The usual dosage of Deca – Durabolin is 200-600 mg a week for male and 50 -100 mg per week for women. The duration of a cycle with Deca is varies from 8 to 12 weeks. Deca-Durabolin can be stacked with Anabol / Sustanon and Testosterone for muscle bulk growth. During a cycle and in PCT it can also be stacked with Clomid/Nolvadex . The side effects of Deca – Durabolin include high blood pressure, blood clotting, increased production of the sebaceous gland, acne, headaches and sexual overstimulation, as well as several typical side effects for women like deepening of voice, hirsutism, acne, high libido and, at, hypertrophy of clitoris.
Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma. If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease. Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids. Edema may occur occasionally with or without congestive heart failure. Concomitant administration of adrenal steroids or ACTH may add to the edema. In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months. This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.
Metabolic effects occurring during anabolic steroid therapy in immobilized patients or those with metastatic breast disease have included osteolytic-induced hypercalcemia. Anabolic steroids affect electrolyte balance, nitrogen retention, and urinary calcium excretion. Edema, with and without congestive heart failure, has occurred. Decreased glucose tolerance requiring adjustments in hyperglycemic control has been noted in diabetic patients. Significant increases in low density lipoproteins (LDL) and decreases in high density lipoproteins (HDL) have occurred. [ Ref ]